Biktarvy drug is the combination of three active ingredients i.e. bictegravir, emtricitabine and tenofovir alafenamide. It is recently approved by food and drug administration on February 7, 2018. It is available in the form of tablet. Biktarvy drug is specially designed for the treatment of HIV infection. Many clinical trials are performed globally and then finally biktarvy drug is approved by food and drug administration with its side effects and adverse effects. Where it is active against HIV infection, there are also some side effects associated with it like worsening of hepatitis B virus infection.
It is not used with other drugs of HIV 1 infection in adults. HIV 1 is a virus which causes AIDS. AIDS is abbreviated as Acquired Immune Deficiency Syndrome). It is still unknown that whether this drugs is safe in children or not. Biktarvy drug is contraindicated with dofetilide and rifampin. Lactation or breast feeding is prohibited while taking Biktarvy drug. Adverse effects of biktarvy was observed in only 5 percent of patients involved in clinical trials.
Biktarvy Mechanism of Action
Biktarvy drug is designed in a fixed dose combination of bictegravir, emtricitabine and tenofovir alafenamide. It is the combination of HIV 1 (human immunodeficiency virus 1) integrase strand transfer inhibitor (INSTI). It also works as two human immunodeficiency virus type 1 nucleoside analog reverse transcriptase inhibitor (NRTI’s). It acts as a nucleoside and inhibit the process of reverse transcription. With the help of these two main functions it actively treat HIV 1 infection especially in adults. Active ingredients used in biktarvy drug work collectively with their specific mechanism of action.
Biktarvy Drug Dose
Biktarvy is a fixed dose combination drug of bictegravir 50 mg, emtricitabine 200 mg and tenofovir alafenamide 25 mg. biktarvy drug is recommended to administer 1 tablet per day which can be taken with food or without food. Biktarvy drug is contraindicated with some drugs like anti-retroviral drugs i.e. rifampin, metformin, acyclovir, Val acyclovir, gentamicin and dofetilide. Dose adjustment is required in case of hepatic impairment, renal abnormality, pregnancy and lactation. Physician recommend not to take biktarvy drug in case of pregnancy and lactation because one of its active ingredient can pass placental barrier and transfer to fetus.
Biktarvy Drug Uses
It is a specially designed complete regimen for treatment of human immunodeficiency virus type 1 infection. Its active ingredients belongs to pharmacological class of human immunodeficiency virus type 1 integrase strand transfer inhibitor and nucleoside reverse analog reverse transcriptase inhibitors. This drug is used in adults who are not taking other anti-retroviral drugs not even in past. There are some limitations in its use like it is not recommended in patients who are virologically suppressed, in patients who are using substitutes of one of its active ingredients, in patients with no treatment failure history of anti-retroviral therapy.
Biktarvy Side effectsAdverse reactions of this drug are as follows.
Nausea, headache, renal impairment can occur or worsen the pre-existing renal impairment, diarrhea, HBV exacerbation, lactic acidosis, immune reconstitution syndrome and hepatomegaly.